Healthcare resource usage of schizophrenia patients initiating long-acting injectable antipsychotics vs oral

A Systematic Review of the Prevalence of Schizophrenia

Saha, S., Chant, D., Welham, J., & McGrath, J. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020141 · Cited by 2,168 · see citing works

Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia: A Comprehensive Review of Recent Literature

Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · see citing works

A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology

McGrath, J., Saha, S., Welham, J., El Saadi, O., MacCauley, C., & Chant, D. (2004) · BMC Medicine · doi:10.1186/1741-7015-2-13 · Cited by 1,072 · see citing works

The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2003

Lehman, A. F., Kreyenbuhl, J. A., Buchanan, R. W., Dickerson, F., Dixon, L. B., Goldberg, R., Green-Paden, L. D., Tenhula, W. N., Boerescu, D. A., Tek, C., et al. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007071 · Cited by 758 · see citing works

Clinical correlates of inpatient suicide

Busch, K. A., Fawcett, J., & Jacobs, D. G. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0105 · Cited by 750 · see citing works

Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia

Weiden, P. J., Kozma, C., Grogg, A., & Locklear, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.8.886 · Cited by 621 · see citing works

The Economic Burden of Schizophrenia in the United States in 2002

Wu, E. Q., Birnbaum, H. G., Shi, L., BALL, D. E., Kessler, R. C., Moulis, M., & Aggarwal, J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0906 · Cited by 614 · see citing works

Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission

Valenstein, M. M., Copeland, L. A., Blow, F. C., McCarthy, J. F., Zeber, J. E., Gillon, L., Bingham, C. R., & Stavenger, T. (2002) · Medical Care · doi:10.1097/00005650-200208000-00002 · Cited by 333 · see citing works

Systematic meta-review of depot antipsychotic drugs for people with schizophrenia

Adams, C. E., Fenton, M., Quraishi, S. N., & David, A. S. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.4.290 · Cited by 286 · see citing works

Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States

Sun, S. X., Liu, G. G., Christensen, D. B., & Fu, A. Z. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x226050 · Cited by 196 · see citing works

The economic burden of schizophrenia

Davies, L. M., & Drummond, M. (1990) · Psychiatric Bulletin · doi:10.1192/pb.14.9.522 · Cited by 168 · see citing works

Relapse and rehospitalization: comparing oral and depot antipsychotics.

Schooler, N. R. (2003) · PubMed · Cited by 141 · see citing works

Patterns and Quality of Treatment for Patients With Schizophrenia in Routine Psychiatric Practice

West, J. C., Wilk, J. E., Olfson, M., Rae, D. S., Marcus, S. C., Narrow, W. E., Pincus, H. A., & Regier, D. A. (2005) · Psychiatric Services · doi:10.1176/appi.ps.56.3.283 · Cited by 114 · see citing works

Characteristics and Use Patterns of Patients Taking First-Generation Depot Antipsychotics or Oral Antipsychotics for Schizophrenia

Shi, L., Ascher‐Svanum, H., Zhu, B., Faries, D. E., Montgomery, W. S., & Marder, S. R. (2007) · Psychiatric Services · doi:10.1176/ps.2007.58.4.482 · Cited by 112 · see citing works

Symptomatic remission in schizophrenia patients: Relationship with social functioning, quality of life, and neurocognitive performance

Brissos, S., Dias, V. V., Balanzá‐Martínez, V., Carita, A. I., & Figueira, M. L. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.001 · Cited by 106 · see citing works

Adherence Assessments and the Use of Depot Antipsychotics in Patients With Schizophrenia

Valenstein, M. M., Copeland, L. A., Owen, R. R., Blow, F. C., & Visnic, S. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n07a08 · Cited by 101 · see citing works

Use of Depot Antipsychotic Medications for Medication Nonadherence in Schizophrenia

West, J. C., Marcus, S. C., Wilk, J. E., Countis, L., Regier, D. A., & Olfson, M. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm137 · Cited by 78 · see citing works

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium

Lambert, T. J. R., Olivares, J. M., Peuskens, J., DeSouza, C., Kozma, C. M., Otten, P., Crivera, C., Jacobs, A., Macfadden, W., Mao, L., et al. (2011) · Annals of General Psychiatry · doi:10.1186/1744-859x-10-10 · Cited by 47 · see citing works

Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE)

Crivera, C., DeSouza, C., Kozma, C. M., Dirani, R. D., Mao, L., & Macfadden, W. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-168 · Cited by 28 · see citing works

Hospitalization and Total Medical Costs for Privately Insured Persons with Schizophrenia

Crown, W. H., Neslusan, C. A., Russo, P. A., Holzer, S., Ozminkowski, R., & Croghan, T. W. (2001) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1023/a:1011139215761 · Cited by 26 · see citing works

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study

Carter, G. B. C., Milton, D. R., Ascher‐Svanum, H., & Faries, D. E. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-143 · Cited by 24 · see citing works

Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder

Citrome, L., Reist, C., Palmer, L. A., Montejano, L. B., Lenhart, G. M., Cuffel, B. J., Harnett, J., & Sanders, K. N. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.09.023 · Cited by 21 · see citing works

Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration

Ren, X. S., Crivera, C., Sikirica, M. V., Dirani, R. D., Qian, S. X., & Kazis, L. E. (2010) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2010.01211.x · Cited by 18 · see citing works

Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies

Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00039-0 · Cited by 369 · see citing works

The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297 · see citing works

Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge

Marcus, S. C., Zummo, J., Pettit, A. R., Stoddard, J. J., & Doshi, J. A. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.9.754 · Cited by 249 · see citing works

Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia

Kaplan, G., Casoy, J., & Zummo, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s53795 · Cited by 201 · see citing works

Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies

Kishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx090 · Cited by 186 · see citing works

Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis

Lin, D., Thompson‐Leduc, P., Ghelerter, I., Nguyen, H., Lafeuille, M., Benson, C. J., Mavros, P., & Lefèbvre, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00815-y · Cited by 126 · see citing works

The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review

Fiorillo, A., Barlati, S., Bellomo, A., Corrivetti, G., Nicolò, G., Sampogna, G., Stanga, V., Veltro, F., Maina, G., & Vita, A. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00293-4 · Cited by 110 · see citing works

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia

Stevens, G. L., Dawson, G., & Zummo, J. (2016) · Early Intervention in Psychiatry · doi:10.1111/eip.12278 · Cited by 109 · see citing works

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia

Potkin, S., Bera, R., Zubek, D., & Lau, G. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-261 · Cited by 98 · see citing works

Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics

Pilon, D., Tandon, N., Lafeuille, M., Kamstra, R. L., Émond, B., Lefèbvre, P., & Joshi, K. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.08.008 · Cited by 98 · see citing works

Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic

Pilon, D., Joshi, K., Tandon, N., Lafeuille, M., Kamstra, R. L., Émond, B., & Lefèbvre, P. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s127623 · Cited by 50 · see citing works

Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics

Shah, A., Xie, L., Kariburyo, F., Zhang, Q., & Gore, M. R. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0786-x · Cited by 47 · see citing works

Identifying patients and clinical scenarios for use of long-acting injectable antipsychotics – expert consensus survey part 1

Sajatovic, M., Ross, R., Legacy, S. N., Correll, C. U., Kane, J. M., DiBiasi, F., Fitzgerald, H., & Byerly, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s167394 · Cited by 44 · see citing works

Approaches to improve adherence to pharmacotherapy in patients with schizophrenia

Shuler, K. M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s59371 · Cited by 41 · see citing works

Why are long-acting injectable antipsychotics still underused?

Bosanac, P., & Castle, D. (2015) · BJ Psych Advances · doi:10.1192/apt.bp.114.013565 · Cited by 35 · see citing works

Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations

ANDERSON, J. P., Icten, Z., Alas, V., Benson, C. J., & Joshi, K. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1507-8 · Cited by 37 · see citing works

Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data

Munday, J., Greene, M., Chang, E. Y., Hartry, A., Yan, T., & Broder, M. S. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1571295 · Cited by 36 · see citing works

The effect of long‐acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta‐analysis

Okoli, C. T. C., Kappi, A. A., Wang, T., Makowski, A., & Cooley, A. T. (2021) · International Journal of Mental Health Nursing · doi:10.1111/inm.12964 · Cited by 36 · see citing works

Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study

Decuypere, F., Sermon, J., Geerts, P., Denee, T. R., de Vos, C. D., Malfait, B., Lamotte, M., & Mulder, C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179049 · Cited by 28 · see citing works

Understanding healthcare burden and treatment patterns among young adults with schizophrenia

Huang, A., Amos, T. B., Joshi, K., Wang, L., & Nash, A. I. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1500370 · Cited by 28 · see citing works

Improving adherence to pharmacological treatment for schizophrenia: a systematic assessment

Curto, M., Fazio, F., Ulivieri, M., Navari, S., Lionetto, L., & Baldessarini, R. J. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1882996 · Cited by 29 · see citing works

Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia

Song, X., Khoury, A. C. E., Brouillette, M. A., Smith, D. M., & Joshi, K. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1615927 · Cited by 27 · see citing works

A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States

Zhang, W., Amos, T. B., Gutkin, S. W., Lodowski, N., Giegerich, E., & Joshi, K. (2018) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s156308 · Cited by 26 · see citing works

Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies

Correll, C. U., Benson, C. J., Émond, B., Patel, C. A., Lafeuille, M., Lin, D., Morrison, L., Ghelerter, I., Lefèbvre, P., & Mavros, P. (2023) · Schizophrenia · doi:10.1038/s41537-023-00334-3 · Cited by 25 · see citing works

Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients

Kamat, S., Offord, S. J., Docherty, J. P., Lin, J., Eramo, A., Baker, R. A., Gutiérrez, B., & Karson, C. N. (2015) · Drugs in Context · doi:10.7573/dic.212267 · Cited by 24 · see citing works

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis

Li, G., Keenan, A., Daskiran, M., Mathews, M., Nuamah, I. F., Orman, C., Joshi, K., Singh, A., Godet, A., Pungor, K., et al. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s322880 · Cited by 23 · see citing works

Use of Long-Acting Injectable Antipsychotics in Inpatients with Schizophrenia Spectrum Disorder in an Academic Psychiatric Hospital in Switzerland

Reymann, S., Schoretsanitis, G., Egger, S., Mohonko, A., Kirschner, M., Vetter, S., Homan, P., Seifritz, E., & Burrer, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030441 · Cited by 23 · see citing works

Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophrenia

Lang, K., Federico, V., Muser, E., Menzin, J. A., & Menzin, J. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.816310 · Cited by 22 · see citing works

A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US

Manjelievskaia, J., Amos, T. B., Khoury, A. C. E., Vlahiotis, A., Cole, A. L., & Juneau, P. L. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1527608 · Cited by 22 · see citing works

The Impact of Prenatal Alcohol Exposure on Addiction Treatment

Grant, T. M., Brown, N. N., Dubovsky, D., Sparrow, J., & Ries, R. K. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31828b47a8 · Cited by 19 · see citing works

Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone

Perlstein, I., Wagner, A. M., Goméni, R., Lamson, M. J., Harary, E., Spiegelstein, O., Kalmanczhelyi, A., Tiver, R., Loupe, P. S., Levi, M., et al. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1078 · Cited by 18 · see citing works

Depot/Long Acting Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder

Özgüven, H. D., & Kır, Y. (2021) · Nöro Psikiyatri Arşivi · doi:10.29399/npa.27480 · Cited by 14 · see citing works

Long-Acting, Injectable Antiretroviral Therapy for the Management of HIV Infection: An Update on a Potential Game-Changer

Barnhart, L. M. M. (2015) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000466 · Cited by 14 · see citing works

Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study

Miron, A. A., Petric, P. S., Teodorescu, A., Ifteni, P. I., Chele, G. E., & Szalontay, A. S. (2023) · Brain Sciences · doi:10.3390/brainsci13020173 · Cited by 13 · see citing works

Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia

Khoury, A. C. E., Pilon, D., Morrison, L., Shak, N., Llaneza, A. J., Kim, E., & Lefèbvre, P. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.2.176 · Cited by 12 · see citing works

The effectiveness of long‐acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia

Fang, S., Liao, D., Huang, C., Hsu, C., Cheng, S., & Shao, Y. J. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2729 · Cited by 11 · see citing works

Formulation development and pharmacokinetic studies of long acting in situ depot injection of risperidone

Dubey, V., & Saini, T. R. (2022) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902022e18809 · Cited by 10 · see citing works

Ethical issues experienced by mental health nurses in the administration of antipsychotic depot and long‐acting intramuscular injections: A qualitative study

Smith, J. P., & Herber, O. R. (2014) · International Journal of Mental Health Nursing · doi:10.1111/inm.12105 · Cited by 10 · see citing works

Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia

Alphs, L. D., Bossie, C. A., Fu, D., Ma, Y.-W., & Sliwa, J. K. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.909409 · Cited by 9 · see citing works

The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia

Khoury, A. C. E., Pilon, D., Morrison, L., Shak, N., Vermette-Laforme, M., Amos, T. B., Kim, E., & Lefèbvre, P. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1558195 · Cited by 10 · see citing works

Effects of oral versus long-acting antipsychotics on social functioning: A psychiatrists’ survey in India

Gundugurti, P. R., Nagpal, R., Sheth, A., Narang, P., Gawande, S., & Singh, V. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.08.002 · Cited by 9 · see citing works

Inpatient prescribing patterns of long-acting injectables and their oral or short-acting injectable equivalent formulations

Liu, Y., Patterson, M. E., Sahil, S., & Stoner, S. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1140969 · Cited by 8 · see citing works

Readmissions, costs, and duration to subsequent outpatient visit after hospital discharge among Medicaid beneficiaries utilizing oral versus long-acting injectable antipsychotics in bipolar disorder or schizophrenia

Tidmore, L. M., Keast, S. L., Waters, H. C., Pareja, K., Cothran, T., & Skrepnek, G. H. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2101819 · Cited by 8 · see citing works

A Pilot Study of Cultural/Racial Differences in Patient Perspectives on Long-Acting Injectable Antipsychotics for the Treatment of Schizophrenia

Potkin, S. G., Bera, R. B., Eramo, A., & Lau, G. (2014) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.pori.050614 · Cited by 7 · see citing works

Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics

Kamstra, R. L., Pilon, D., Lefèbvre, P., Émond, B., & Joshi, K. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1442822 · Cited by 7 · see citing works

Impact of schizophrenia relapse definition on the comparative effectiveness of oral versus injectable antipsychotics: A systematic review and meta‐analysis of observational studies

Cristarella, T., Castillon, G., Nepveu, J.-F., & Moride, Y. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.915 · Cited by 7 · see citing works

Discrepancy in Taiwanese psychiatrists’ preferences for long-acting injectable antipsychotics across facilities: a nationwide questionnaire survey

Liu, C.-H., Tsai, P.-H., & Chen, C. Y. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s154490 · Cited by 5 · see citing works

Problems with the Administration of Antipsychotic Drugs in Depot Formulations in the Treatment of Schizophrenia

Ranković, A., & Јаnkovic, S. (2017) · AFMN Biomedicine · doi:10.2478/afmnai-2018-0007 · Cited by 5 · see citing works

Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics

Kheloussi, S. S., Oberlin, J., Trauger, M., & Testa, N. D. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.10.1130 · Cited by 4 · see citing works

Clinical effectiveness of paliperidone palmitate 3‐monthly and 1‐monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database

Chiang, C. N., Chinen, M., Daskiran, M., Wakamatsu, A., & Turkoz, I. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12473 · Cited by 4 · see citing works

Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal

García-Carmona, J. A., & Pappa, S. (2023) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s339170 · Cited by 4 · see citing works

Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments

Vallejo-Aparicio, L. A., García, V. N., Hernández‐Novoa, B., Casado, G. D. M., Jodar, F., Pinel, M., & Callejo, D. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09595-4 · Cited by 4 · see citing works

New Targets for the Management of Schizophrenia

Dilbaz, N. (2015) · Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology · doi:10.5455/bcp.20151125024949 · Cited by 5 · see citing works

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia

Wilson, M. R., Gutiérrez, B., Offord, S. J., Blanchette, C., Eramo, A., Earnshaw, S., & Kamat, S. (2016) · Drugs in Context · doi:10.7573/dic.212273 · Cited by 4 · see citing works

Sociodemographic Factors and Medication Administration Factors Affecting Re – Hospitalization in Patients with Schizophrenia – Spectrum Disorders

Papakostas, S., Dar, A., & Ratna, L. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09756-z · Cited by 3 · see citing works

Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study

Cai, Q., Patel, C. A., Kim, E., Connolly, N., Tunceli, O., & Khoury, A. C. E. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00913-w · Cited by 3 · see citing works

Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia

Weiden, P. J., Strand, L. N., Doane, M. J., Arevalo, C., McGrory, J. A., Achtyes, E. D., Harvey, P. D., Kane, J. M., Saklad, S. R., Trotter, J. P., et al. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s528018 · Cited by 1 · see citing works

Risperidone Long-acting Injectable versus Paliperidone Palmitatefor Community-dwelling Patients with Schizophrenia

Webster, A. C., & Phillips, S. (2015)

Quality of life of schizophrenic patients with or without depot neuroleptics

Simić-Medojević, I., & Burgić-Radmanović, M. (2015) · Scripta Medica · doi:10.5937/scrimed1501060s

SHORT-TERM COST-EFFECTIVENESS OF SECOND-GENERATION LONG-ACTING INJECTABLE ANTIPSYCHOTICS AS COMPARED WITH ORAL ANTIPSYCHOTICS IN PREVENTING REHOSPITALIZATION OR TREATMENT SWITCH IN PATIENTS WITH SCHIZOPHRENIA

Mantaian, T. (2019) · doi:10.23860/thesis-mantaian-tyler-2019

Characteristics and Utilization Patterns of Medicare Beneficiaries Initiating Long-Acting Injectable Antipsychotic Medications

Grabner, M., Chiang, Y.-Y., Teng, C.-C., dosReis, S., & Harris, K. (2026) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s567370

Real-world adherence and healthcare resource utilization following transition to aripiprazole once-every-2-months from oral or once-monthly aripiprazole among patients diagnosed with schizophrenia in the United States

Harrsen, K., Yildirim, M., Beckham, C., Lynum, K. S. B., Atkins, N., Baser, O., Rodchenko, K., Urganus, A., Awasthi, S., & Nag, S. S. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2722697

Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics

Shah, A., Xie, L., Kariburyo, F., Zhang, Q., & Gore, M. R. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0786-x · Cited by 47 · see citing works

Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia

Fu, A. Z., Pesa, J. A., Lakey, S. L., & Benson, C. J. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03895-2 · Cited by 27 · see citing works

Impact of treatment with long‑acting injectable antipsychotics on hospitalization and relapse rates in schizophrenia spectrum disorders: a 3‑year follow-up mirror‑image study

de Filippis, R., Aloi, M., Cimino, A., Carbone, E. A., Rania, M., D’Onofrio, E., Kane, J. M., Schoretsanitis, G., Segura‐Garcìa, C., & Fazio, P. D. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251403263 · Cited by 1 · see citing works

Long-Acting Injectable Versus Oral Antipsychotics in Reducing Hospitalization Outcomes in Schizophrenia: A Repeat Mirror Image StudyPreprint

Chawla, A., Sivaseelan, A., Johnston, K., & Chawla, B. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4298124

Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia: A Systematic Review and Meta-Analysis of Mirror-Image Studies

Kishimoto, T., Nitta, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08440 · Cited by 427 · see citing works